Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer

Description

The purpose of the study is to determine the frequency of systemic metastasis in node positive breast cancer following chemotherapy and surgery. Participants will be asked to spend about 6 months in this study. Participants will undergo a computed tomography (CT) screening of the thorax, abdomen, and pelvis at baseline prior to adjuvant radiation therapy and another CT screening of the thorax, abdomen, and pelvis at 6 months if the baseline CT is found to be negative.

Conditions

Breast Cancer, Node-positive Breast Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of the study is to determine the frequency of systemic metastasis in node positive breast cancer following chemotherapy and surgery. Participants will be asked to spend about 6 months in this study. Participants will undergo a computed tomography (CT) screening of the thorax, abdomen, and pelvis at baseline prior to adjuvant radiation therapy and another CT screening of the thorax, abdomen, and pelvis at 6 months if the baseline CT is found to be negative.

Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer Following Neoadjuvant Chemotherapy and Surgery

Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer

Condition
Breast Cancer
Intervention / Treatment

-

Contacts and Locations

Tampa

Moffitt Cancer Center, Tampa, Florida, United States, 33612

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Histologic diagnosis of breast cancer with documentation of ER/PR/HER2 status.
  • * HR+ will be defined as ER and/or PR ≥ 10%. To be classified as HER2+ disease, overexpression of HER2 by either IHC or in-situ hybridization is necessary as defined by the ASCO / CAP Guidelines27. Triple negative will be classified as ER and PR \<10% and HER2-.
  • * Node positive HER2+ and triple negative breast cancer (ypN+) following receipt of neoadjuvant chemotherapy. HR+/HER2- patients should have ypN2 or ypN3 disease following receipt of neoadjuvant chemotherapy and surgery.
  • * Patient must have completed a minimum of 8 weeks of standard neoadjuvant chemotherapy consisting of an anthracycline and/or taxane-based regimen. To include HER2 directed therapy for HER2+ patients.
  • * Age ≥ 18.
  • * Life expectancy ≥ 6 months.
  • * Eastern Cooperative Oncology Group performance status 0 to 2.
  • * Patients must be able to understand and the willingness to sign an informed consent for study procedures.
  • * Ability to understand and stated willingness to comply with all study procedures and availability for the duration of the study.
  • * Prior diagnosis of systemic metastases.
  • * Patients with prior history of non-breast cancer malignancies should have NED ≥ 2 years excluding adequately treated non-melanoma skin cancer, in situ cancer of the cervix or bladder.
  • * Contraindication towards CT IV contrast.
  • * Chronic kidney disease stage IV or V or end stage renal disease (CrCl \<30 ml/min).

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

H. Lee Moffitt Cancer Center and Research Institute,

Kamran Ahmed, PRINCIPAL_INVESTIGATOR, Moffitt Cancer Center

Matthew Mills, PRINCIPAL_INVESTIGATOR, Moffitt Cancer Center

Study Record Dates

2026-08